J. A. Moler Cuiral
In this work two designs are proposed to jointly estimate the slope and the target dose in the phase-I of a clinicial trial. We will focus on one of them: the c-compound design which incorporates two restrictions. The first one does not allow doses with toxicity larger than a chosen percentile, the second restriction guarantees an efficiency with respect to the c-optimal larger than "e"
Keywords: Experimental designs, phase-I clinical trial
Scheduled
GT06.DEX3 Invited Session
November 8, 2023 12:00 PM
CC1: Audience